Exploration of poly (ADP‐ribose) polymerase inhibitor resistance in the treatment of BRCA1/2‐mutated cancer

• Published in: Genes chromosomes & cancer 2024-05, Vol.63 (5), p.e23243-n/a
• Main Authors: Wu, Shuyi, Yao, Xuanjie, Sun, Weiwei, Jiang, Kaitao, Hao, Jie
• Format: Article
• Language: English
• Subjects: Antineoplastic Agents - pharmacology; Antineoplastic Agents - therapeutic use; BRCA1 protein; BRCA1 Protein - genetics; BRCA1/2 gene; BRCA2 Protein - genetics; Breast Neoplasms - drug therapy; Breast Neoplasms - genetics; Cisplatin; DNA damage; DNA repair; Drug Resistance, Neoplasm - genetics; Female; Homologous recombination; Homologous recombination repair; Humans; Lethality; Mutants; Mutation; Neoplasms - drug therapy; Neoplasms - genetics; PARPi; Poly(ADP-ribose) polymerase; Poly(ADP-ribose) Polymerase Inhibitors - pharmacology; Poly(ADP-ribose) Polymerase Inhibitors - therapeutic use; Replication; replication gaps; Tumorigenesis; Tumors
• ISSN: 1045-2257; 1098-2264; 1098-2264
• DOI: 10.1002/gcc.23243

Breast cancer susceptibility 1/2 (BRCA1/2) genes play a crucial role in DNA damage repair, yet mutations in these genes increase the susceptibility to tumorigenesis. Exploiting the synthetic lethality mechanism between BRCA1/2 mutations and poly(ADP‐ribose) polymerase (PARP) inhibition has led to the development and clinical approval of PARP inhibitor (PARPi), representing a milestone in targeted therapy for BRCA1/2 mutant tumors. This approach has paved the way for leveraging synthetic lethality in tumor treatment strategies. Despite the initial success of PARPis, resistance to these agents diminishes their efficacy in BRCA1/2‐mutant tumors. Investigations into PARPi resistance have identified replication fork stability and homologous recombination repair as key factors sensitive to PARPis. Additionally, studies suggest that replication gaps may also confer sensitivity to PARPis. Moreover, emerging evidence indicates a correlation between PARPi resistance and cisplatin resistance, suggesting a potential overlap in the mechanisms underlying resistance to both agents. Given these findings, it is imperative to explore the interplay between replication gaps and PARPi resistance, particularly in the context of platinum resistance. Understanding the impact of replication gaps on PARPi resistance may offer insights into novel therapeutic strategies to overcome resistance mechanisms and enhance the efficacy of targeted therapies in BRCA1/2‐mutant tumors.